Epigenetic therapy in lung cancer - Role of microRNAs

Frontiers in Oncology

Volumn 3 JUN, Issue , 2013, Pages

  Rothschild, Sacha I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarker; Diagnosis; Lung cancer; microRNA; Prognosis; Therapy

Indexed keywords

CISPLATIN; DNA METHYLTRANSFERASE 3A; MICRORNA; MICRORNA 101; MICRORNA 106A; MICRORNA 107; MICRORNA 124A; MICRORNA 126; MICRORNA 145; MICRORNA 17; MICRORNA 182; MICRORNA 185; MICRORNA 18A; MICRORNA 192; MICRORNA 19A; MICRORNA 19B 1; MICRORNA 203; MICRORNA 20A; MICRORNA 21; MICRORNA 210; MICRORNA 212; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 30A; MICRORNA 31; MICRORNA 519C; MICRORNA 92A 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; EPIGENETICS; GENE EXPRESSION; HUMAN; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84885730364     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00158     Document Type: Review

References (93)

1. Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., et al. (2011a). Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409. doi:10.1056/NEJMoa1102873.
2. Aberle, D. R., Berg, C. D., Black, W. C., Church, T. R., Fagerstrom, R. M., Galen, B. I., et al. (2011b). The National Lung Screening Trial: overview and study design. Radiology 258, 243-253. doi:10.1148/radiol.10091808.
3. Arora, S., Ranade, A. R., Tran, N. L., Nasser, S., Sridhar, S., Korn, R. L., et al. (2011). MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int. J. Cancer 129, 2621-2631. doi:10.1002/ijc.25939.
4. Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J. P., and Vansteenkiste, J. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351-360. doi:10.1056/NEJMoa031644.
5. Barba, M., Felsani, A., Rinaldi, M., Giunta, S., Malorni, W., and Paggi, M. G. (2011). Reducing the risk of overdiagnosis in lung cancer: a support from molecular biology. J. Cell. Physiol. 226, 2213-2214. doi:10.1002/jcp.22558.
6. Barshack, I., Lithwick-Yanai, G., Afek, A., Rosenblatt, K., Tabibian-Keissar, H., Zepeniuk, M., et al. (2010). MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol. Res. Pract. 206, 578-584. doi:10.1016/j.prp.2010.03.005.
7. Besse, B., and Le Chevalier, T. (2012). Developments in the treatment of early NSCLC: when to use chemotherapy. Ann. Oncol. 23(Suppl. 10), x52-x59. doi:10.1093/annonc/mds347.
8. Bian, H. B., Pan, X., Yang, J. S., Wang, Z. X., and De, W. (2011). Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J. Exp. Clin. Cancer Res. 30, 20. doi:10.1186/1756-9966-30-20.
9. Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchinetti, F., et al. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 3713-3718. doi:10.1073/pnas.1100048108.
10. Bronte, G., Rizzo, S., La Paglia, L., Adamo, V., Siragusa, S., Ficorella, C., et al. (2010). Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 36(Suppl. 3), S21-S29. doi:10.1016/S0305-7372(10)70016-5.
11. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 15524-15529. doi:10.1073/pnas.242606799.
12. Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., et al. (2005). A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801. doi:10.1056/NEJMoa050995.
13. Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 101, 2999-3004. doi:10.1073/pnas.0307323101.
14. Carleton, M., Cleary, M. A., and Linsley, P. S. (2007). MicroRNAs and cell cycle regulation. Cell Cycle 6, 2127-2132. doi:10.4161/cc.6.17.4641.
15. Cha, S. T., Chen, P. S., Johansson, G., Chu, C. Y., Wang, M. Y., Jeng, Y. M., et al. (2010). MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 70, 2675-2685. doi:10.1158/0008-5472.CAN-09-2448.
16. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997-1006. doi:10.1038/cr.2008.282.
17. Cheng, A. M., Byrom, M. W., Shelton, J., and Ford, L. P. (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33, 1290-1297. doi:10.1093/nar/gki200.
18. Chin, L. J., Ratner, E., Leng, S., Zhai, R., Nallur, S., Babar, I., et al. (2008). A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 68, 8535-8540. doi:10.1158/0008-5472.CAN-08-2129.
19. Chivukula, R. R., and Mendell, J. T. (2008). Circular reasoning: microRNAs and cell-cycle control. Trends Biochem. Sci. 33, 474-481. doi:10.1016/j.tibs.2008.06.008.
20. Cho, W. C., Chow, A. S., and Au, J. S. (2009). Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 45, 2197-2206. doi:10.1016/j.ejca.2009.04.039.
21. Donnem, T., Eklo, K., Berg, T., Sorbye, S. W., Lonvik, K., Al-Saad, S., et al. (2011). Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J. Transl. Med. 9, 6. doi:10.1186/1479-5876-9-6.
22. Du, L., Schageman, J. J., Subauste, M. C., Saber, B., Hammond, S. M., Prudkin, L., et al. (2009). miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol. Cancer Res. 7, 1234-1243. doi:10.1158/1541-7786.MCR-08-0507.
23. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805-15810. doi:10.1073/pnas.0707628104.
24. Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., et al. (2012). MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 109, E2110-E2116. doi:10.1073/pnas.1209414109.
25. Feng, S., Cong, S., Zhang, X., Bao, X., Wang, W., Li, H., et al. (2011). MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res. 39, 6669-6678. doi:10.1093/nar/gkr232.
26. Ferlay, J., Parkin, D. M., and Steliarova-Foucher, E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765-781. doi:10.1016/j.ejca.2009.12.014.
27. Gallardo, E., Navarro, A., Vinolas, N., Marrades, R. M., Diaz, T., Gel, B., et al. (2009). miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30, 1903-1909. doi:10.1093/carcin/bgp219.
28. Galluzzi, L., Morselli, E., Vitale, I., Kepp, O., Senovilla, L., Criollo, A., et al. (2010). miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 70, 1793-1803. doi:10.1158/0008-5472.CAN-09-3112.
29. Gao, W., Yu, Y., Cao, H., Shen, H., Li, X., Pan, S., et al. (2010). Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed. Pharmacother. 64, 399-408. doi:10.1016/j.biopha.2010.01.018.
30. Garber, K. (2010). ALK, lung cancer, and personalized therapy: portent of the future? J. Natl. Cancer Inst. 102, 672-675. doi:10.1093/jnci/djq184.
31. Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S. S., Ngankeu, A., et al. (2009). miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16, 498-509.
32. Garofalo, M., Quintavalle, C., Di Leva, G., Zanca, C., Romano, G., Taccioli, C., et al. (2008). MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27, 3845-3855. doi:10.1038/onc.2008.6.
33. Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., et al. (2005). A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628-9632. doi:10.1158/0008-5472.CAN-05-2352.
34. Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., et al. (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28, 1721-1726. doi:10.1200/JCO.2009.24.9342.
35. Incoronato, M., Garofalo, M., Urso, L., Romano, G., Quintavalle, C., Zanca, C., et al. (2010). miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 70, 3638-3646. doi:10.1158/0008-5472.CAN-09-3341.
36. Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070. doi:10.1158/0008-5472.CAN-05-1783.
37. Izzotti, A., Calin, G. A., Arrigo, P., Steele, V. E., Croce, C. M., and De Flora, S. (2009). Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 23, 806-812. doi:10.1096/fj.08-121384.
38. Janku, F., Stewart, D. J., and Kurzrock, R. (2010). Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol. 7, 401-414. doi:10.1038/nrclinonc.2010.64.
39. Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., et al. (2007). The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67, 7713-7722. doi:10.1158/0008-5472.CAN-07-1083.
40. Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635-647. doi:10.1016/j.cell.2005.01.014.
41. Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., et al. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U.S.A. 105, 3903-3908. doi:10.1073/pnas.0712321105.
42. Landi, M. T., Zhao, Y., Rotunno, M., Koshiol, J., Liu, H., Bergen, A. W., et al. (2010). MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16, 430-441. doi:10.1158/1078-0432.CCR-09-1736.
43. Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., et al. (2009). Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 27, 2030-2037. doi:10.1200/JCO.2008.19.4134.
44. Lee, Y. S., and Dutta, A. (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21, 1025-1030. doi:10.1101/gad.1540407.
45. Lu, Y., Govindan, R., Wang, L., Liu, P. Y., Goodgame, B., Wen, W., et al. (2012). MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 33, 1046-1054. doi:10.1093/carcin/bgs100.
46. Lu, Y., Thomson, J. M., Wong, H. Y., Hammond, S. M., and Hogan, B. L. (2007). Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev. Biol. 310, 442-453. doi:10.1016/j.ydbio.2007.08.007.
47. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139. doi:10.1056/NEJMoa040938.
48. Matsubara, H., Takeuchi, T., Nishikawa, E., Yanagisawa, K., Hayashita, Y., Ebi, H., et al. (2007). Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 26, 6099-6105. doi:10.1038/sj.onc.1210425.
49. Mott, J. L., Kobayashi, S., Bronk, S. F., and Gores, G. J. (2007). Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26, 6133-6140. doi:10.1038/sj.onc.1210436.
50. Muniyappa, M. K., Dowling, P., Henry, M., Meleady, P., Doolan, P., Gammell, P., et al. (2009). MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur. J. Cancer 45, 3104-3118. doi:10.1016/j.ejca.2009.09.014.
51. Nakamura, T., Canaani, E., and Croce, C. M. (2007). Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc. Natl. Acad. Sci. U.S.A. 104, 10980-10985. doi:10.1073/pnas.0704559104.
52. Navarro, A., Marrades, R. M., Vinolas, N., Quera, A., Agusti, C., Huerta, A., et al. (2009). MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 76, 162-169. doi:10.1159/000201569.
53. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500. doi:10.1126/science.1099314.
54. Pao, W., and Girard, N. (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180. doi:10.1016/S1470-2045(10)70087-5.
55. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311. doi:10.1073/pnas.0405220101.
56. Patnaik, S. K., Kannisto, E., Knudsen, S., and Yendamuri, S. (2010). Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70, 36-45. doi:10.1158/0008-5472.CAN-09-3153.
57. Prenzel, N., Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8, 11-31. doi:10.1677/erc.0.0080011.
58. Rabinowits, G., Gercel-Taylor, C., Day, J. M., Taylor, D. D., and Kloecker, G. H. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 10, 42-46. doi:10.3816/CLC.2009.n.006.
59. Rai, K., Takigawa, N., Ito, S., Kashihara, H., Ichihara, E., Yasuda, T., et al. (2011). Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther. 10, 1720-1727. doi:10.1158/1535-7163.MCT-11-0220.
60. Raponi, M., Dossey, L., Jatkoe, T., Wu, X., Chen, G., Fan, H., et al. (2009). MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69, 5776-5783. doi:10.1158/0008-5472.CAN-09-0587.
61. Rothschild, S. I., Tschan, M. P., Federzoni, E. A., Jaggi, R., Fey, M. F., Gugger, M., et al. (2012a). MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 31, 4221-4232. doi:10.1038/onc.2011.578.
62. Rothschild, S. I., Tschan, M. P., Jaggi, R., Fey, M. F., Gugger, M., and Gautschi, O. (2012b). MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J. Thorac. Oncol. 7, 1069-1077. doi:10.1097/JTO.0b013e31824fe976.
63. Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., et al. (2006). Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435-443. doi:10.1016/j.ccr.2006.04.020.
64. Sampson, V. B., Rong, N. H., Han, J., Yang, Q., Aris, V., Soteropoulos, P., et al. (2007). MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 6, 9762-9770. doi:10.1158/0008-5472.CAN-07-2462.
65. Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., et al. (2009). The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14, 253-263. doi:10.1634/theoncologist.2008-0232.
66. Schaefer, U., Voloshanenko, O., Willen, D., and Walczak, H. (2007). TRAIL: a multifunctional cytokine. Front. Biosci. 12:3813-3824. doi:10.2741/2354.
67. Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., et al. (2009). MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. U.S.A. 106, 12085-12090. doi:10.1073/pnas.0905234106.
68. Semenza, G. L. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634. doi:10.1038/onc.2009.441.
69. Shen, J., Todd, N. W., Zhang, H., Yu, L., Lingxiao, X., Mei, Y., et al. (2011). Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 91, 579-587. doi:10.1038/labinvest.2010.194.
70. Sun, Y., Fang, R., Li, C., Li, L., Li, F., Ye, X., et al. (2010). Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem. Biophys. Res. Commun. 396, 501-507. doi:10.1016/j.bbrc.2010.04.127.
71. Taguchi, A., Yanagisawa, K., Tanaka, M., Cao, K., Matsuyama, Y., Goto, H., et al. (2008). Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 68, 5540-5545. doi:10.1158/0008-5472.CAN-07-6460.
72. Takahashi, Y., Forrest, A. R., Maeno, E., Hashimoto, T., Daub, C. O., and Yasuda, J. (2009). MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS ONE 4:e6677. doi:10.1371/journal.pone.0006677.
73. Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753-3756. doi:10.1158/0008-5472.CAN-04-0637.
74. Tan, X., Qin, W., Zhang, L., Hang, J., Li, B., Zhang, C., et al. (2011). A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin. Cancer Res. 17, 6802-6811. doi:10.1158/1078-0432.CCR-11-0419.
75. Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., et al. (2010). Regression of murine lung tumors by the let-7 microRNA. Oncogene 29, 1580-1587. doi:10.1038/onc.2009.445.
76. Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., et al. (2008). Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875-886. doi:10.1016/j.cell.2008.02.019.
77. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261. doi:10.1073/pnas.0510565103.
78. Voortman, J., Goto, A., Mendiboure, J., Sohn, J. J., Schetter, A. J., Saito, M., et al. (2010). MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 70, 8288-8298. doi:10.1158/0008-5472.CAN-10-1348.
79. Wang, G., Mao, W., Zheng, S., and Ye, J. (2009). Epidermal growth factor receptor-regulated miR-125a-5p-a metastatic inhibitor of lung cancer. FEBS J. 276, 5571-5578. doi:10.1111/j.1742-4658.2009.07238.x.
80. Wang, Q., Wang, S., Wang, H., Li, P., and Ma, Z. (2012). MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. Exp. Biol. Med. (Maywood) 237, 227-235. doi:10.1258/ebm.2011.011192.
81. Wang, R., Wang, Z. X., Yang, J. S., Pan, X., De, W., and Chen, L. B. (2011). MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 30, 2644-2658. doi:10.1038/onc.2010.642.
82. Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S., and Leedman, P. J. (2009). Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J. Biol. Chem. 284, 5731-5741. doi:10.1074/jbc.M804280200.
83. Weidhaas, J. B., Babar, I., Nallur, S. M., Trang, P., Roush, S., Boehm, M., et al. (2007). MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 67, 11111-11116. doi:10.1158/0008-5472.CAN-07-2858.
84. Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., et al. (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 19, 1053-1059. doi:10.1093/annonc/mdn006.
85. Wu, X., Piper-Hunter, M. G., Crawford, M., Nuovo, G. J., Marsh, C. B., Otterson, G. A., et al. (2009). MicroRNAs in the pathogenesis of lung cancer. J. Thorac. Oncol. 4, 1028-1034. doi:10.1097/JTO.0b013e3181a99c77.
86. Xie, Y., Todd, N. W., Liu, Z., Zhan, M., Fang, H., Peng, H., et al. (2010). Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67, 170-176. doi:10.1016/j.lungcan.2009.04.004.
87. Xing, L., Todd, N. W., Yu, L., Fang, H., and Jiang, F. (2010). Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 23, 1157-1164. doi:10.1038/modpathol.2010.111.
88. Xu, H. I., Cheung, Y., Guo, H. F., and Cheung, N. K. (2009). MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 69, 6275-6281. doi:10.1158/0008-5472.CAN-08-4517.
89. Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198.
90. Yu, L., Todd, N. W., Xing, L., Xie, Y., Zhang, H., Liu, Z., et al. (2010). Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127, 2870-2878. doi:10.1002/ijc.25289.
91. Yu, S. L., Chen, H. Y., Chang, G. C., Chen, C. Y., Chen, H. W., Singh, S., et al. (2008). MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13, 48-57. doi:10.1016/j.ccr.2007.12.008.
92. Zhang, J. G., Guo, J. F., Liu, D. L., Liu, Q., and Wang, J. J. (2011). MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J. Thorac. Oncol. 6, 671-678. doi:10.1097/JTO.0b013e318208eb35.
93. Zhong, M., Ma, X., Sun, C., and Chen, L. (2010). MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem. Biol. Interact. 184, 431-438. doi:10.1016/j.cbi.2010.01.025.